Riyaz Shah

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto et al. · Journal of Clinical Oncology · 2013 · 3.2K citations

Medicine, Oncology, Pharmacology +17

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

Suresh S. Ramalingam, Yi Cheng, C. Zhou et al. · Annals of Oncology · 2018 · 355 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng et al. · Nature Communications · 2023 · 239 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

James Chih‐Hsin Yang, Lecia V. Sequist, Caicun Zhou et al. · Annals of Oncology · 2016 · 188 citations

Pharmacy, Oncology, Pharmacology +17